Debate de expertos
Priorización de la OCT tras la COVID-19
10 junio 2020
· 50 MIN VER
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original.image_file.100.100.file/dr-ike-ahmed.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original.image_file.360.360.file/dr-ike-ahmed.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original.image_file.768.768.file/dr-ike-ahmed.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original.image_file.1024.1024.file/dr-ike-ahmed.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original./dr-ike-ahmed.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original./dr-ike-ahmed.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/dr-ike-ahmed.jpg/_jcr_content/renditions/original./dr-ike-ahmed.jpg"})
Autor
Dr. Ike Ahmed
Prism Eye Institute, Canadá
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original.image_file.100.100.file/schlenker-m.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original.image_file.360.360.file/schlenker-m.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original.image_file.768.768.file/schlenker-m.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original.image_file.1024.1024.file/schlenker-m.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original./schlenker-m.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original./schlenker-m.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/myzeiss/peer-insights/free/ophthalmic-diagnostics/275-oct-prioritization-post-covid-19/images/schlenker-m.jpg/_jcr_content/renditions/original./schlenker-m.jpg"})
Autor
Dr. Matt Schlenker
Kensington Eye Institute, Canadá
RESUMEN
Uso y priorización de la OCT para la gestión del glaucoma tras la COVID-19
En este oportuno debate participan los expertos Ike Ahmed, doctorado en medicina, y Matt Schlenker, doctorado en medicina, que comparten sus ideas sobre cuál es el mejor modo de tratar a los pacientes con glaucoma y priorizar la OCT tras la COVID-19. Durante estos tiempos, en los que se acumulan los pacientes a los que se permite volver a los centros sanitarios para tener consultas o pruebas médicas de forma presencial, sugieren que se tengan en cuenta cuatro puntos:
- Cómo evaluar con teleoftalmología a los pacientes que padecen glaucoma
- Cómo entender los modos más eficientes de evaluar utilizando la obtención de imágenes, al tiempo que se tiene en cuenta la correlación de estructura-función
- Cómo aprovechar las huellas únicas para la evaluación de enfermedades y la identificación de artefactos
- El valor del análisis de la progresión tras la COVID-19